295 related articles for article (PubMed ID: 20844763)
1. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
2. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Avogadri F; Zappasodi R; Yang A; Budhu S; Malandro N; Hirschhorn-Cymerman D; Tiwari S; Maughan MF; Olmsted R; Wolchok JD; Merghoub T
Cancer Immunol Res; 2014 May; 2(5):448-58. PubMed ID: 24795357
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
[TBL] [Abstract][Full Text] [Related]
5. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
7. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
Leitner WW; Hwang LN; deVeer MJ; Zhou A; Silverman RH; Williams BR; Dubensky TW; Ying H; Restifo NP
Nat Med; 2003 Jan; 9(1):33-9. PubMed ID: 12496961
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Osada T; Berglund P; Morse MA; Hubby B; Lewis W; Niedzwiecki D; Yang XY; Hobeika A; Burnett B; Devi GR; Clay TM; Smith J; Kim Lyerly H
Cancer Immunol Immunother; 2012 Nov; 61(11):1941-51. PubMed ID: 22488274
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
10. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.
Moran TP; Burgents JE; Long B; Ferrer I; Jaffee EM; Tisch RM; Johnston RE; Serody JS
Vaccine; 2007 Sep; 25(36):6604-12. PubMed ID: 17675184
[TBL] [Abstract][Full Text] [Related]
11. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
12. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.
Bridle BW; Boudreau JE; Lichty BD; Brunellière J; Stephenson K; Koshy S; Bramson JL; Wan Y
Mol Ther; 2009 Oct; 17(10):1814-21. PubMed ID: 19603003
[TBL] [Abstract][Full Text] [Related]
13. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Hubby B; Talarico T; Maughan M; Reap EA; Berglund P; Kamrud KI; Copp L; Lewis W; Cecil C; Norberg P; Wagner J; Watson A; Negri S; Burnett BK; Graham A; Smith JF; Chulay JD
Vaccine; 2007 Nov; 25(48):8180-9. PubMed ID: 17961878
[TBL] [Abstract][Full Text] [Related]
14. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
15. Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.
Wolchok JD; Srinivasan R; Perales MA; Houghton AN; Bowne WB; Blachere NE
Cancer Immun; 2001 Aug; 1():9. PubMed ID: 12747770
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
17. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
18. Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.
Zappasodi R; Merghoub T
Immunotherapy; 2015; 7(9):981-97. PubMed ID: 26310996
[TBL] [Abstract][Full Text] [Related]
19. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.
Xu G; Smith T; Grey F; Hill AB
Biochem Biophys Res Commun; 2013 Jul; 437(2):287-91. PubMed ID: 23811402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]